These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33065463)

  • 1. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
    Fusco N; Vaira V; Righi I; Sajjadi E; Venetis K; Lopez G; Cattaneo M; Castellani M; Rosso L; Nosotti M; Clerici M; Ferrero S
    Lung Cancer; 2020 Dec; 150():53-61. PubMed ID: 33065463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
    Yang H; Berezowska S; Dorn P; Zens P; Chen P; Peng RW; Marti TM; Kocher GJ; Schmid RA; Hall SRR
    Theranostics; 2022; 12(1):167-185. PubMed ID: 34987640
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
    de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
    J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
    Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
    Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
    Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Death Ligand 1 (PD-L1) Expression and CD8 + Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy.
    Ordner J; Gutierrez Amezcua JM; Marcus A; Shukla PS
    Int J Gynecol Pathol; 2023 Jul; 42(4):364-375. PubMed ID: 35639400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
    Tazzari M; Brich S; Tuccitto A; Bozzi F; Beretta V; Spagnuolo RD; Negri T; Stacchiotti S; Deraco M; Baratti D; Camisaschi C; Villa A; Vergani B; Rivoltini L; Pilotti S; Castelli C
    J Immunol Res; 2018; 2018():5804230. PubMed ID: 30510965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
    J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
    J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
    Marcq E; Siozopoulou V; De Waele J; van Audenaerde J; Zwaenepoel K; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits EL
    Oncoimmunology; 2017; 6(1):e1261241. PubMed ID: 28197385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
    Yamada N; Oizumi S; Kikuchi E; Shinagawa N; Konishi-Sakakibara J; Ishimine A; Aoe K; Gemba K; Kishimoto T; Torigoe T; Nishimura M
    Cancer Immunol Immunother; 2010 Oct; 59(10):1543-9. PubMed ID: 20567822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
    Salaroglio IC; Kopecka J; Napoli F; Pradotto M; Maletta F; Costardi L; Gagliasso M; Milosevic V; Ananthanarayanan P; Bironzo P; Tabbò F; Cartia CF; Passone E; Comunanza V; Ardissone F; Ruffini E; Bussolino F; Righi L; Novello S; Di Maio M; Papotti M; Scagliotti GV; Riganti C
    J Thorac Oncol; 2019 Aug; 14(8):1458-1471. PubMed ID: 31078776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.